Day: March 16, 2022

March 16, 2022

• Philips Vue PACS interoperability enhances access, quality of care, and patient experience in Scottish Breast Screening Program 
• Image sharing across regional breast screening centers helps better manage the post COVID-19 backlog of screening appointments

Amsterdam, the Netherlands and Orlando, Florida, USA – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and NHS National Services Scotland, a non-departmental public body that provides advice and services to National Health Service (NHS) Scotland, today revealed the impact of the COVID-19 pandemic on the Scottish Breast Screening Program (SBSP), and the measures taken to deal with the backlog of delayed appointments. Philips’ vendor-neutral Vue PACS (Picture Archiving and Communication System) allows the SBSP’s six breast screening centers and its mobile screening units to interoperate with Scotland’s national PACS system, increasing access to breast screening for Scotland’s rural communities, enhancing patient choice, and streamlining diagnostic and treatment workflows.

Female breast cancer is the world’s most common form of cancer, with approximately 2.26 million new cases in 2020 [1]. Nearly 1,000 women per year die from the disease in Scotland alone [2]. Through the partnership between Philips and NHS National Services Scotland, as many as 270,000 women in Scotland between the ages of 50 and 70 are invited for breast screening (mammography) every year [3]. However, according to Public Health Scotland (PHS), between April 2020 and December 2020 during the height of the COVID-19 pandemic, there was a 19% fall in the number of women diagnosed with early-stage breast cancer (down 35% at stage 1 and 15% at stage 2 diagnosis) [4]. This drop was largely attributed to the SBSP being paused between March 30 and August 3, 2020, creating a backlog of appointments, diagnoses, and treatments.

Philips Picture Archiving and Communication System (Vue PACS) is a scalable and modular image management solution that provides hospitals and related institutions with scalable (local and wide area) PACS functionalities. The interoperability of Philips’ Vue PACS has been a key factor in reducing that backlog, offering enhanced connectivity between the screening program’s regional screening centers, as well as interoperability with Scotland’s Global PACS system.

“The national reporting function enabled by the Global PACS solution allows centers to report and support each other. For instance, in the case of a staffing issue due to absences from sickness amongst readers, cases for reporting can rapidly pile up. The use of this function allows readers from across Scotland to provide mutual aid and assistance in ensuring all centers are at a similar level in reporting,” said Dr. Gerald Lip, Clinical Director of NE Scotland Breast Screening Service.

Streamlining workflows, improving access to better care
The interoperability of Philips Vue PACS with Scotland’s Global PACS system makes an individual patient’s current and prior mammography images available to all NHS Scotland hospitals, enabling clinicians to compare new scans with prior studies irrespective of where they were performed in Scotland. It also allows the program’s regional screening centers to support one another – for example, when staff shortages limit the ability of any one center to cope with the volume of images that need to be read. As a result, patients benefit from faster diagnoses and better-informed treatment plans.

“This latest collaboration with the NHS in Scotland further demonstrates our commitment to deliver patient-centric solutions designed to deliver the right information at the right time to help improve the patient experience and help advance the path to precision care,” said Kees Wesdorp, Chief Business Leader of Precision Diagnosis at Philips. “The Scottish Breast Screening Program has revolutionized breast cancer care in Scotland, ensuring that no matter where patients live, they have a better chance of receiving an early diagnosis and timely treatment. Philips is proud to be working with the team at NHS Scotland to continually improve the technology, scope and scale of the program.”

Philips’ diagnostic informatics portfolio supports hospitals and imaging centers with intelligent, scalable, secure and interoperable solutions which connect people, technology and data to support clinical decisions at every point of care. Philips’ end-to-end portfolio of enterprise informatics solutions enables patients, clinicians and hospital administrators to fully harness the power of information and translate data into actionable insights – a critical next step to advance precision care.

Philips will be showcasing its enterprise imaging solutions that securely connect and facilitate the sharing of information among patients and their care teams across health systems at the upcoming HIMSS Global meeting, March 14 – March 18 in Orlando, Florida, USA. For more information on how the company’s advanced analytics and intelligent informatics support clinicians at the point-of-care by providing clinical insights and improving collaboration among clinical care teams, visit www.philips.com/himss and follow @PhilipsLiveFrom for #HIMSS22 updates throughout the event.

[1] Ferlay J, Colombet M, Soerjomataram I, Parkin DM, Piñeros M, Znaor A, Bray F. Cancer statistics for the year 2020: An overview. Int J Cancer. 2021 Apr 5. doi: 10.1002/ijc.33588. Epub ahead of print. PMID: 33818764. https://pubmed.ncbi.nlm.nih.gov/33818764/
[2] https://www.nhsinform.scot/healthy-living/screening/breast/breast-screening
[3] https://www.isdscotland.org/Health-topics/Cancer/Breast-screening/
[4] https://publichealthscotland.scot/publications/cancer-staging-data-using-2018-to-2020-dce-data-the-impact-of-covid-19/cancer-staging-data-using-2018-to-2020-dce-data-the-impact-of-covid-19/

For further information, please contact:

Kathy O’Reilly
Philips Global Press Office
Tel.: +1 978-221-8919
E-mail: kathy.oreilly@philips.com

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and well-being, and enabling better outcomes across the health continuum – from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2021 sales of EUR 17.2 billion and employs approximately 78,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

Attachment

• Two doctors reviewing mammogram case

March 16, 2022

Integration of SecureLink critical access management technology with Philips Remote Services framework provides advanced security for remote technical and clinical support

Amsterdam, the Netherlands and Orlando, Florida, USA – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the expansion of its medical device cybersecurity services portfolio at HIMSS22. Philips is introducing Secure Remote Access Management Service [1], leveraging the broad set of security capabilities enabled by the integration of SecureLink’s critical access management and governance technology with Philips Remote Services’ secure connectivity framework for technical and clinical support. The services provide benefits for healthcare providers including increased uptime, clinical performance, and advanced security to help protect access to their clinical solutions and medical devices.

“We are continuously expanding the foundation of Philips Cybersecurity Services and this type of integration is a strong complement to our offering, giving our customers more options for building robust cybersecurity programs,” said Gal Gnainsky, Head of Security at Philips. “As healthcare providers’ cybersecurity requirements continue to increase, partnering with SecureLink highlights Philips’ focus on offering best-in-class solutions to provide more secure access management and protect health networks down to granular device level.”

Philips Remote Services: a key enabler of digital transformation in healthcare
Remote services have become an essential component of the digital transformation of healthcare. Philips’ portfolio of remote services is utilized to monitor key performance parameters for many clinical systems and devices on a continuous basis and alert customers of potential issues and rectify them, often remotely, before they result in system or device failures that interrupt patient care. During the COVID-19 pandemic, they played an important role in helping to keep hospitals operational at a time when on-site maintenance was logistically difficult. Applying artificial intelligence (AI) and predictive analytics to the acquired data, they are also important to support the goals of zero system downtime, increased efficiency, and seamless uninterrupted workflows.

Secure access to combat increasing cyber threats in healthcare
By integrating with SecureLink’s vendor privileged access management and governance capabilities, the Philips Remote Services portfolio now provides additional capabilities, offering a uniform level of security, visibility, traceability, and audit capability needed for critical access management and data security. SecureLink’s solutions allow customers to manage privileged access sessions with rich audit logging, limiting access to relevant devices and systems and granting only ‘need to know’ permissions required to monitor or maintain them.

“SecureLink is the industry leader in critical access management, empowering organizations to secure access to their most valuable assets, including networks, systems, and data. By partnering with Philips we are extending the web of security offered by our critical access management technology across their customer base and the healthcare ecosystem at large,” said Joel Burleson Davis, Chief Technology Officer of SecureLink. “With cybercrime in healthcare at an all-time high [2], partnerships like that between SecureLink and Philips are essential to protecting healthcare systems, data and patients from today’s increasingly sophisticated cyber threats.”

Security by design
The Philips Cybersecurity Services portfolio comprises an end-to-end suite of technologies and services to safeguard customers’ medical systems, devices, and related software regardless of vendor, helping empower the digital transformation in healthcare. The company’s approach to cybersecurity is characterized by end-to-end ‘Security by Design’ principles that focus on security during product design, development, testing, and deployment right through to in-use performance monitoring, system updates, and incident response management. Philips also contributes to the development of national and international cybersecurity standards for medical devices, and its Cybersecurity Services portfolio aligns with global cybersecurity best practices and standards. The Philips Remote Services operating environment implements security controls that meet the internationally recognized ISO/IEC 27001 Information Security Management Systems standard.

For more information on Philips’ full portfolio of connected informatics solutions being showcased in booth #2501 at the HIMSS22 Global Health Conference & Exhibition, please visit www.philips.com/himss and follow @PhilipsLiveFrom for #HIMSS22 updates throughout the event.

For Philips Product Security statement and white papers, click here.

[1] Philips Secure Remote Access Management Service will be available for selected Philips Remote Service enabled systems in the USA and Canada from Q3 2022. Philips will continue to expand Secure Remote Access Management Service to support more systems and remote service solutions.
[2] https://cybersecurity.criticalinsight.com/2021_H2_HealthcareDataBreachReport

For further information, please contact:

Anna Hogrebe
Philips Global Press Office
Tel.: +1 416 270 6757
E-Mail: anna.hogrebe@philips.com

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and well-being, and enabling better outcomes across the health continuum – from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2021 sales of EUR 17.2 billion and employs approximately 78,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

Attachment

• Physician reads radiology images

Spring update to support tax, revenue recognition and regional compliance mandates to help customers expand globally

San Francisco, CA, March 16, 2022 (GLOBE NEWSWIRE) — Fresh off its recent round of funding, Chargebee, the leading subscription management platform, today announced the industry’s first e-invoicing service for high-performing SaaS and subscription-model businesses as the centerpiece of its Spring 2022 Product Release. The release includes updates geared towards enabling growth and efficiency for Chargebee customers, including taxation and revenue recognition features and a new Marketplace to automate billing workflows through a library of customizable integrations.

E-Invoicing

Countries across the world, including Brazil, France, Finland, Germany and India, are already mandating e-invoicing for Business to Government (B2G) transactions as a way of modernizing and simplifying tax reporting and payment and several countries, including Poland and France, will join Italy, Mexico and Chile in mandating e-invoicing for B2B transactions as early as 2023. Chargebee’s e-invoicing service will allow businesses seeking to expand operations globally to easily comply with local e-invoicing mandates and serve B2G and B2B customers in new regions.

“Chargebee has solved a huge problem for us,” said Gabriele Proni, co-founder and CTO of Voxloud, an Italian-based communications company. “Italy has some of the strictest e-invoicing mandates in the entire world, and without Chargebee’s e-invoicing service, we would have had to spend countless hours sending them out manually. Chargebee came in and helped automate the process, saving our team from spending unnecessary time and power and allowed us to focus on doing what we do best.”

Marketplace 

Automation is key to ensuring that modern billing systems are able to remain flexible and adaptable for businesses to succeed, especially for SaaS and subscription models, and is taking on a large role in Chargebee’s 2022 Spring Product Release.

Chargebee’s Marketplace enables businesses to build their billing systems on top of Chargebee, allowing for more and better integrations by connecting merchants with a wide catalog of available integrations to choose from. Marketplace improves integrations with other apps end-to-end, from discovery to sign-up, automating billing workflows and use cases.

Taxation and Revenue Recognition 

In addition to e-invoicing and Marketplace, Chargebee adds taxation and revenue recognition capabilities to handle real-time changes based on customer demands. Through automation, Chargebee is providing subscription businesses with a new way to sync billing information and improve an organization’s financial efficiency and enabling them to meet the growing list of compliance requirements, including Value-Added Tax (“VAT” in Europe) and Tax Deduction at Source (“TDS” in India).

Compliance

As Chargebee continues to support expansion into new and different geographies, customers need not worry about the growing list of regional and local compliances they will face. Chargebee is now certified as HIPAA compliant with the “Privacy Rule”, “Security Rule” and “Breach Notification” as per the HIPAA Portability and Accountability Act to support customers in the healthcare industry. In addition, Chargebee is also compliant with PCI and GDPR standards and adheres to ISO, SOC1, SOC2 and MFA standards.

Global Growth 

“Global and product expansion is a big part of Chargebee’s 2022-and-beyond roadmap, and we know that our customers are always looking to scale up, increase capabilities and enter new territories,” said John Pearce, Vice President of Product Management at Chargebee.  “There are tons of constantly changing rules and regulations that could inhibit growth, and our new offerings are designed to help our customers offload these concerns and focus on building and maintaining business.”

The Chargebee Spring 2022 Product Release full list of features includes:

• E-invoicing for India and the European Union
• Tax Withholding (TDS)
• Subscriptions Marketplace
• New Salesforce Integration UX
• GST Breakdown (Australia)
• Revenue Recognition through acquisition of RevLock
• Retention through acquisition of Brightback
• Receivables through acquisition of numberz
• HIPAA Compliance
• SOC-2 Compliance

These latest product enhancements come on the heels of a $250 million funding round that valued the company at $3.5 billion and was geared towards Chargebee’s global expansion. Recent acquisitions of Brightback (customer retention), RevLock (revenue recognition) and numberz (receivables) will also strengthen Chargebee’s offerings to enable end-to-end management of subscriptions and revenue data.

To learn more about Chargebee’s Spring 2022 Product Release, please visit https://www.chargebee.com/blog/spring-release-2022.

Penny Desatnik
Chargebee
penny@chargebee.com

SHANGHAI, China, March 16, 2022 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced today that the first patient was dosed in its Phase III trial of VV116 for the treatment of moderate to severe COVID-19. The study is an international multicenter, randomized, double-blind, controlled Phase III study to evaluate the efficacy and safety of VV116 against standard therapy in subjects with moderate to severe COVID-19. The primary endpoint is the percentage of patients who progress to critical/severe COVID-19 patients or all-cause mortality within 29 days. VV116 is an oral nucleoside analog anti-SARS-CoV-2 investigational drug jointly developed by Junshi Biosciences and Vigonvita Life Sciences Co., Ltd. (“Vigonvita”).

In addition, Junshi Biosciences has also initiated an international multi-center, double-blind, randomized, placebo-controlled, phase II/III clinical study (NCT05242042) with Vigonvita, which aims to evaluate the efficacy, safety and pharmacokinetics of VV116 in the early treatment of mild to moderate COVID-19 patients. The primary endpoint is the percentage of patients who progress to critical/severe COVID-19 patients or all-cause mortality within 29 days. First patient of the study has been enrolled and dosed in China, and the study is being conducted in multiple centers around the world.

Junshi Biosciences and Vigonvita have completed three Phase I studies evaluating the safety, tolerability, and pharmacokinetics of VV116 in healthy Chinese subjects, with preliminary results showing good clinical safety. In addition, a randomized, open-label, controlled Phase II clinical trial of VV116 was completed in subjects with moderate to severe COVID-19 in Uzbekistan in 2021, which enrolled a total of about 450 subjects. Subjects were divided into two VV116 groups (200mg and 300mg doses of VV116 orally, twice daily for 5 days) and one control group of standard therapy, with each group of about 150 subjects. The results of the study indicate that the two different doses of VV116 showed favorable safety and efficacy in the treatment of both moderate and severe COVID-19 patients, in comparison with standard therapy. Based on the positive results, VV116 has been approved for the treatment of moderate to severe COVID-19 patients in Uzbekistan in late 2021.

About VV116

VV116 is a new oral nucleoside analog anti-SARS-CoV-2 drug that inhibits the replication of SARS-CoV-2. Preclinical studies have shown that VV116 exhibited significant anti-SARS-CoV-2 effects in vivo and in vitro, had antiviral activity against both the original strain of SARS- CoV-2 and the major known variants (Alpha, Beta, Delta, and Omicron), and exhibited high oral bioavailability and good chemical stability.

VV116 is jointly developed by three institutes of the Chinese Academy of Sciences (Shanghai Institute of Materia Medica, Wuhan Institute of Virology, and Xinjiang Technical Institute of Physics and Chemistry), Central Asian Center of Drug Discovery and Development of Chinese Academy of Sciences/China-Uzbekistan Medicine Technical Park (the Belt and Road Joint Laboratory of the Ministry of Science and Technology), Vigonvita, and Junshi Biosciences. In September 2021, Junshi Biosciences entered into a collaboration with Vigonvita to jointly undertake the clinical development and commercialization of VV116 in the cooperation territory (worldwide except five Central Asian countries (Kazakhstan, Uzbekistan, Kyrgyzstan, Tajikistan, Turkmenistan), Russia, North Africa (Egypt, Libya, Tunisia, Algeria, Morocco, Sudan), and the Middle East (19 countries including Saudi Arabia, Iran, Iraq, Turkey, Israel, etc.)).

VV116 has been approved for treatment of moderate to severe COVID-19 patients in Uzbekistan.

About Junshi Biosciences
Founded in December 2012, Junshi Biosciences (HKEX: 1877; SSE: 688180) is an innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of innovative therapeutics. The company has established a diversified R & D pipeline comprising over 45 drug candidates, with five therapeutic focus areas covering cancer, autoimmune, metabolic, neurological, and infectious diseases. Junshi Biosciences was the first Chinese pharmaceutical company that obtained marketing approval for anti-PD-1 monoclonal antibody in China. Its first-in-human anti-BTLA antibody for solid tumors was the first in the world to be approved for clinical trials by the FDA and NMPA and its anti-PCSK9 monoclonal antibody was the first in China to be approved for clinical trials by the NMPA. In early 2020, Junshi Biosciences joined forces with the Institute of Microbiology of Chinese Academy of Science and Eli Lilly to co-develop JS016 (etesevimab), China’s first neutralizing fully human monoclonal antibody against SARS-CoV-2. JS016 administered with bamlanivimab has been granted Emergency Use Authorizations (EUA) in more than 15 countries and regions worldwide. The JS016 program is a part of our continuous innovation for disease control and prevention of the global pandemic. Junshi Biosciences has over 2,500 employees in the United States (San Francisco and Maryland) and China (Shanghai, Suzhou, Beijing and Guangzhou). For more information, please visit: http://junshipharma.com.

Junshi Biosciences Contact Information
IR Team:
Junshi Biosciences
info@junshipharma.com
+ 86 021-2250 0300

Solebury Trout
Bob Ai
bai@gobyglobal.com
+ 1 646-389-6658

PR Team:
Junshi Biosciences
Zhi Li
zhi_li@junshipharma.com
+ 86 021-6105 8800

Near the Ocean, Hear the Ocean in Southampton

146 Foster Crossing Southampton

146 Foster Crossing Southampton

SOUTHAMPTON, N.Y., March 16, 2022 (GLOBE NEWSWIRE) — Looking for turnkey, inviting elegance with proximity to beaches? Look no further. Positioned just four houses from the Atlantic Ocean and sequestered behind tall privet hedges and a security gate lies this new stucco and shingle manse in the Village of Southampton. A European sensibility is evident here in the three-level, high-quality home, from the superb architecture to the exceptional build and execution using the finest of materials.

From the time one enters this sun-filled residence, you know you’ve arrived at a place created for idyllic seaside living. The inviting gravel and slate courtyard leads to the front entry Dutch door. Once inside, breathe in the interior architecture of leaded glass doors, Venetian plaster walls, wide white oak floors and curated rooms full of beautiful details in this nearly six-bedroom residence. South-facing rooms spill out to wide and deep terraces, several of which offer the option of being covered, allowing for outdoor enjoyment in all four seasons.

A sensible floor plan includes a sitting room, a sunroom, a first-floor guest wing featuring two bedrooms and two bathrooms, a mud-room and a laundry room. The formal dining (though, this home feels more relaxed and inviting than formal) and large living room with fireplace each have access to separate terraces and views of the garden. The heart of the house is home to the spectacular double-height kitchen, which needs to be seen to be appreciated, with slabs of stunning marble, walls of glass and an impressive ceiling height of 22 feet.

Upstairs, find the master suite with private balcony terrace and garden views. Leave the windows open at night and the sound of the ocean nearby lulls one to sleep. Two large very “special guest” suites are nearby and provide a true sense of high quality. The lower level of this home features a gym, media-lounge areas, bunkroom full bath and a wine cellar. Outside spaces include the 60-foot swimming pool, which anchors the structured and established landscaping, terraces and al-fresco dining areas. The outdoor kitchen is sensibly located as is the large outdoor shower perfect for freshening up after returning from a cool swim in the Atlantic Ocean nearby. Other exterior features include the porte-cochere, vegetable garden and attached two-car garage. This home was inspired by those who truly understand high-quality and sophisticated elegance and is now available for immediate enjoyment.

For more information, please contact:

Tim Davis, Licensed Associate Real Estate Broker

Corcoran Group Real Estate
24 Main Street Southampton, NY 11968
T: +1 631.702.9211 or +1 516.356.5736
E: tgdavis@corcoran.com
W: www.timdavishamptons.com

To view the listing, Click Here.

Related Images

Image 1: 146 Foster Crossing Southampton

146 Foster Crossing Southampton

This content was issued through the press release distribution service at Newswire.com.

Attachment

• 146 Foster Crossing Southampton

Industry-Leading Automotive AI Software Now Available on World-Class Automotive Grade AI Perception, Fusion and Central Processing Platform

Ambarella and Helm.ai High-End ADAS Software Integration

New perception software release for the Ambarella CVflow® AI SoC architecture makes Helm.ai’s high-end advanced driver assistance system (ADAS) software available to the strong ecosystem of customers and partners built around the Ambarella platform.

SANTA CLARA, Calif. and MENLO PARK, Calif., March 16, 2022 (GLOBE NEWSWIRE) — Ambarella, Inc. (NASDAQ: AMBA), an edge AI semiconductor and software company, and Helm.ai, a developer of next-generation AI software, today announced a new perception software release for the Ambarella CVflow^® AI SoC architecture that makes Helm.ai’s high-end advanced driver assistance system (ADAS) software available to the strong ecosystem of customers and partners built around the Ambarella platform. This new integration allows both companies to rapidly iterate on technical approaches that meet the latest automotive market needs, while offering combined hardware and software solutions to joint customers.

“We found it easy to integrate into Ambarella’s CVflow hardware, and this platform has enabled us to dramatically lower power consumption while achieving new benchmarks in overall system efficiency for running our cutting edge, high-end ADAS software,” said Helm.ai CEO Vlad Voroninski. “Ambarella’s CV2FS automotive grade SoC platform achieves cutting edge performance for a 5.5 TOPS solution when running our software. We are also planning to port our software to the latest CV3 domain controller SoC family as part of the ongoing offerings for our joint customers and partners.”

Helm.ai and Ambarella first demonstrated the initial integration of Helm.ai technology at CES 2020. At this year’s event, the two companies demonstrated an integration of the Helm.ai full 360° surround-view camera perception stack for L2+/L3 and autonomous driving on Ambarella’s automotive grade CV2FS SoCs. Today’s new integration leverages all hardware capabilities of the Ambarella CVflow architecture to optimize the performance of Helm.ai’s AI algorithms while meeting the accuracy goals expected from an automotive grade solution.

“Helm.ai’s novel approach to training AI systems for computer vision, called Deep Teaching, offers far-reaching implications for the future of computer vision and autonomous driving, as well as other industries such as robotics, aviation, manufacturing and even retail,” said Ambarella President and CEO Fermi Wang. “This new integration combines Helm.ai’s high-end ADAS software and our CV2FS automotive grade AI SoC platform to offer industry-leading performance per watt. In the next stage of this collaboration, we are using Ambarella’s scalable CVflow platform to port Helm.ai’s advanced ADAS software onto our new CV3 SoC for single-chip perception of multiple sensors. This central domain controller SoC family can simultaneously process HD radar and vision captures, while providing fusion and path planning for ADAS to L4 autonomous vehicles.”

About Helm.ai
Helm.ai is building the next generation of AI software for high-end ADAS, L4 autonomous driving and robotics. Founded in November 2016 in Menlo Park, CA, the company has re-envisioned the way AI software is built to make truly scalable autonomous driving a reality. For more information on Helm.ai, including its products, SDK and open career opportunities, visit https://www.helm.ai/ or find Helm.ai on LinkedIn.

About Ambarella
Ambarella’s products are used in a wide variety of human and computer vision applications, including video security, advanced driver assistance systems (ADAS), electronic mirror, drive recorder, driver/cabin monitoring, autonomous driving and robotics applications. Ambarella’s low-power systems-on-chip (SoCs) offer high-resolution video compression, advanced image processing and powerful deep neural network processing to enable intelligent perception, fusion and central processing systems to extract valuable data from high-resolution video and radar streams. For more information, please visit www.ambarella.com.

Ambarella Contacts

• Media contact: Eric Lawson, elawson@ambarella.com, +1 480-276-9572
• Investor contact: Louis Gerhardy, lgerhardy@ambarella.com, +1 408-636-2310
• Sales contact: www.ambarella.com/about/contact/inquiries

Helm.ai Contacts

• Media contact: Vanessa Camones, vanessa.camones@helm.ai, +1 415-412-2856
• Sales contact: Seung Yang, seung.yang@helm.ai, +1 248-925-2437

All brand names, product names, or trademarks belong to their respective holders. Ambarella reserves the right to alter product and service offerings, specifications, and pricing at any time without notice.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/420e51ff-2171-421d-bfa2-61bf19527253

Congenica to Provide Tertiary Analysis for Whole Genome Sequencing for Hong Kong Genome Project

Cambridge, United Kingdom – 16 March 2022 – Congenica, the digital health company enabling rapid and accurate analysis of complex genomic data to transform people’s lives, today announces that it has been selected to provide tertiary analysis for whole genome sequencing services for the Hong Kong Genome Project (HKGP), the first large-scale genome sequencing initiative in Hong Kong.

The HKGP, being implemented by the Hong Kong Genome Institute (HKGI) and funded by the HKSAR Government, serves as a catalyst for Hong Kong to establish a genome database of the local population, testing infrastructure and talent pool, all of which will facilitate clinical applications of genomic medicine and scientific research to benefit patients and their families.

To support the pilot phase of HKGP, Congenica will provide its clinical decision support platform for the tertiary analysis of 5,000 genome sequences in order to identify disease-causing variants within the DNA of HKGP’s participants and their family members who are affected by undiagnosed diseases and hereditary cancer. Employing AI and automation for highest efficiency and diagnostic yield, the Congenica platform is chosen for its clinical utility and ability to support whole genome data analysis at scale.

Kamraan Shariff, Chief Business Development Officer of Congenica, said, “The service contract awarded by HKGI highlights the growing international recognition of the power of our platform, particularly for large–scale whole genome analyses. This builds on our role as the exclusive clinical decision support platform and sole provider of genomic data analysis for rare disease cases in the UK Genomic Medicine Service, the world’s first health system to provide whole genome sequencing to patients at a national level. We are proud to have been selected by HKGI and share their ultimate goal of delivering more precise diagnoses and more effective treatments for patients.”

**ENDS**

About Congenica

Congenica is a digital health company enabling the rapid analysis and interpretation of genomic data, empowering researchers and clinicians to provide life-changing answers that improve wellbeing and disease management. Congenica’s world-leading software enables rapid genomic data analysis at scale and is the only product of its kind that has received the CE Mark under the In Vitro Diagnostics Directive.

A recognised leader in the genomic analysis of rare diseases and inherited cancer, Congenica is expanding its platform into new indications such as somatic cancer, next generation non- invasive preconception and pre-natal diagnosis and wellness, helping to deliver a future where clinical genomics is fully integrated into healthcare.

Based on pioneering research from the Wellcome Sanger Institute and the UK NHS, Congenica has a global footprint supporting leading international laboratories, academic medical centres and biopharmaceutical companies and is the exclusive Clinical Decision Support partner for the NHS Genomic Medicine Service.

For more information visit www.congenica.com.

Contact details for editorial enquiries:

Becky Lamont, Marketing Communications Manager

Email: rebecca.lamont@congenica.com

Consilium Strategic Communications

Chris Gardner, Angela Gray, David Daley

Email: Congenica@consilium-comms.com

Tel: +44 (0)20 3709 570

Please click HERE for press release in Mandarin.